Schizophrenia News and Research

Latest Schizophrenia News and Research

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Neural differences may help explain prevalence of mental disorders in boys

Many mental health disorders, such as autism and schizophrenia, produce changes in social behavior or interactions. The frequency and/or severity of these disorders is substantially greater in boys than girls, but the biological basis for this difference between the two sexes is unknown.

18 Nov 2010

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.

18 Nov 2010

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

18 Nov 2010

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

PrecisionMed Inc. today announced at the Society for Neuroscience annual meeting in San Diego, enrollment of the first subject into the PrecisionMed Multiple Sclerosis (MS) Registry. The PrecisionMed MS Registry is a biological sample bank of DNA and serial RNA, CSF, serum and plasma associated with serial clinical testing utilizing PrecisionMed's clinical data procurement and storage capabilities.

17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

Researchers develop human cell-based model of Rett syndrome

A groundbreaking study published Friday in the leading scientific journal, Cell, revealed that a team of investigators had successfully generated nerve cells using skin cells from four individuals with Rett syndrome. The study, funded in part by IRSF, was led by Dr. Alysson Muotri at the University of California, San Diego--a leading researcher in the stem cell field.

16 Nov 2010

Researchers find additional work of oxytocin hormone

New human research suggests the chemical oxytocin dubbed the "cuddle hormone" because of its importance in bonding between romantic partners and mothers and children also influences feelings of well-being and sensitivity to advertising.

15 Nov 2010

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs. For example, the issue of the antipsychotic drug ziprasidone lengthening the QTc interval, a possible indicator of life-threatening heart arrhythmias, has demanded much attention among clinicians since the drug was introduced in 2001.

15 Nov 2010

ARYx third quarter net loss decreases from $8.2 million to $2.5 million

ARYx Therapeutics, Inc. today provided an update on its business operations and released its financial results for the third quarter of 2010.

15 Nov 2010

Diffusion Tensor Imaging MRI technique helps produce satisfactory images of nerve bundles

Standard MRI scans have so far been unable to produce satisfactory images of nerve bundles. However, this is now possible by an MRI technique called Diffusion Tensor Imaging (DTI). Matthan Caan succeeded in improving the DTI method during his PhD research at TU Delft, enabling him to produce more accurate images of the damage that radiotherapy and chemotherapy cause in young leukaemia patients.

15 Nov 2010

Spontaneous mutations can cause mental retardation

Dutch geneticists affiliated with the Radboud University Nijmegen Medical Centre present as a novel research paradigm that spontaneous mutations are an important cause of mental retardation.

15 Nov 2010

Cortex third quarter net loss decreases to $528,000

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $528,000, or $0.01 per share, for the quarter ended September 30, 2010, compared with a net loss applicable to common stock of approximately $3,243,000 or $0.06 per share, for the prior year quarter.

12 Nov 2010

Eight students to receive Hartford Doctoral Fellowship in geriatric social work

Eight outstanding students have been chosen as the newest recipients of the prestigious Hartford Doctoral Fellowship in geriatric social work. The program is funded by the John A. Hartford Foundation, administered by The Gerontological Society of America, and directed by James Lubben, DSW, MPH.

12 Nov 2010

Researchers study Rett neurons in a Petri dish

A collaborative effort between researchers at the Salk Institute for Biological Studies and the University of California, San Diego, successfully used human induced pluripotent stem (iPS) cells derived from patients with Rett syndrome to replicate autism in the lab and study the molecular pathogenesis of the disease.

12 Nov 2010

Research unveils epigenetic function of MECP2 gene tht cause neuropsychiatric disorders

The laboratory of Huda Zoghbi, where the discovery that mutations in the gene MECP2 cause the severe childhood neurological disorder Rett Syndrome was made, has taken yet another step toward unraveling the complex epigenetic functions of this gene, implicated also in cases of autism, bipolar disease and childhood onset schizophrenia. The November 11 issue of Nature reports that removing MECP2 from a small group of neurons that typically make the inhibitory neurotransmitter, GABA, recapitulates many symptoms of Rett as well as numerous neuropsychiatric disorders.

12 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

In a remarkable and unprecedented collaboration NEWMEDS (Novel Methods leading to NeW MEdications in Depression and Schizophrenia) have pooled resources to bring together data of 23,401 anonymized patients from 67 trials on 11 compounds in over 25 countries to form the single largest database of clinical trial data ever amassed in psychiatric research.

10 Nov 2010

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

9 Nov 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

Scientists solve receptor structure that responds to neurotransmitter dopamine

Neural differences may help explain prevalence of mental disorders in boys

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Researchers develop human cell-based model of Rett syndrome

Researchers find additional work of oxytocin hormone

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

ARYx third quarter net loss decreases from $8.2 million to $2.5 million

Diffusion Tensor Imaging MRI technique helps produce satisfactory images of nerve bundles

Spontaneous mutations can cause mental retardation

Cortex third quarter net loss decreases to $528,000

Eight students to receive Hartford Doctoral Fellowship in geriatric social work

Researchers study Rett neurons in a Petri dish

Research unveils epigenetic function of MECP2 gene tht cause neuropsychiatric disorders

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

NEWMEDS launches largest database to advance drug development for depressio, schizophrenia

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Schizophrenia News and Research

Latest Schizophrenia News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in